Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 3/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 2/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8085675 | 0.84 | HPGDS (0.64) | KMT2AL3MBTL1MEN1NPC1CNR2 | |
| SCHEMBL8085672 | 0.82 | NR3C1 (0.51) | KMT2AL3MBTL1MEN1NPC1CNR2 | |
| SCHEMBL2907928 | 0.78 | ADORA2A (0.60) | KMT2AL3MBTL1MEN1NPC1HTT | |
| SCHEMBL22573588 | 0.76 | HPGDS (0.58) | L3MBTL1CNR2THRBROCK1HPGDS | |
| SCHEMBL22573822 | 0.76 | HPGDS (0.64) | KMT2AL3MBTL1MEN1NPC1CNR2 | |
| SCHEMBL920392 | 0.75 | NSD2 (0.66) | KMT2AL3MBTL1NSD2ALDH1A1EGLN1 | |
| SCHEMBL15759019 | 0.74 | KMT2A (0.51) | KMT2AL3MBTL1NPC1CNR2HTT | |
| SCHEMBL14769150 | 0.74 | RXFP1 (0.52) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL4745582 | 0.74 | CNR2 (0.69) | CNR2 | |
| SCHEMBL14391615 | 0.74 | PLAU (0.71) | KMT2AL3MBTL1MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550473-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCQ, PRKCZ, PRKCH | KMT2A 2345/4885L3MBTL1 3977/4885MEN1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.